Holen Sie sich die Stockscreener-App
527.05
0.45%
2.34
Vorhandelsmarkt:
528.00
0.95
+0.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$524.71
Offen:
$525.5
24-Stunden-Volumen:
1.23M
Relative Volume:
0.55
Marktkapitalisierung:
$195.86B
Einnahmen:
$45.20B
Nettoeinkommen (Verlust:
$6.87B
KGV:
28.98
EPS:
18.1888
Netto-Cashflow:
$6.75B
1W Leistung:
+0.69%
1M Leistung:
+9.34%
6M Leistung:
-14.84%
1J Leistung:
+22.36%
1-Tages-Spanne:
$522.60
$533.08
1-Wochen-Bereich:
$506.82
$533.08
52-Wochen-Spanne:
$403.36
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
527.05 | 195.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.05 | 140.88B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
563.57 | 44.46B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
269.95 | 38.66B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
134.29 | 37.93B | 7.23B | 1.41B | 1.09B | 4.979 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Thermo Fisher stock holds steady as investors await catalysts - ad-hoc-news.de
Thermo Fisher Looks To Block Former Exec's Move To Fortrea - Law360
Thermo Fisher stock holds steady as investors focus on life-science demand - ad-hoc-news.de
Thermo Fisher Scientific (TMO) Announces Consistent Quarterly Di - GuruFocus
Thermo Fisher Scientific Keeps Quarterly Dividend at $0.47 per Share, Payable Oct. 15 to Holders of Record Sept. 15 - Moomoo
Thermo Fisher declares $0.47 quarterly dividend By Investing.com - Investing.com Nigeria
Thermo Fisher Scientific Announces Quarterly Dividend - Yahoo Finance
Thermo Fisher Scientific to lay off 69 - In Business Madison
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market - MarketWatch
Thermo Fisher Q2 Preview: Buy Before The Recovery (NYSE:TMO) - Seeking Alpha
Thermo Fisher Scientific strengthens its life science platform as demand for lab tools stays resilie - AD HOC NEWS
Thermo Fisher Sci. steady after recent updates. Investors focus on healthcare demand - Ad-hoc-news.de
Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market - MarketWatch
Thermo Fisher expands its scientific footprint as investors assess long-term growth - Ad-hoc-news.de
Thermo Fisher Scientific Launches GENESYS G5 UV-Visible Spectrophotometer Series - Food Safety Magazine
Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG - PR Newswire
Thermo Fisher's Patheon becomes exclusive third-party CDMO for KinetiSol technology - Manufacturing Chemist
Thermo Fisher (TMO) Wins FBI Approval For Rapid DNA Tool In Crime Investigations - Yahoo Finance
Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026 - AOL.com
Thermo Fisher Scientific Launches New Quality Assurance Software - Clinical Lab Products
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches - AOL.com
TMO Maintained by Evercore ISI Group -- Price Target Lowered to $570 - GuruFocus
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
Evercore Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $570 - Moomoo
Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $570 From $575 - marketscreener.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: Evaluating The 13.91% Potential Upside - DirectorsTalk Interviews
Environmental DNA Market Set to Surge to USD 5.61 Billion by 2031 with 10.2% CAGR - GlobeNewswire Inc.
Shapiro Administration Highlights the Need for Funding to Grow Pennsylvania’s Innovation Economy During Visit to Thermo Fisher Scientific in Dauphin County - PA Department of Community & Economic Development (.gov)
Thermo Fisher launches LabLink 360 software to streamline QC review workflows - Select Science
Kavaljer Investmentbolagsfond June 2026 – Thermo Fisher and Siemens New Holdings - marketscreener.com
Arcturus Therapeutics Holdings Inc. And Thermo Fisher Scientific Inc. Announce Strategic Collaboration To Advance ARCT-032 For Cystic Fibrosis - marketscreener.com
Arcturus Therapeutics Announces Strategic Collaboration With Thermo Fisher Scientific - TradingView
Thermo Fisher to back Arcturus (NASDAQ: ARCT) ARCT-032 Phase 3 and manufacturing - Stock Titan
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis - Business Wire
Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market - MarketWatch
Thermo Fisher NanoDrop OneC from Thermo Fisher Scientific Inc.compact UV-Vis spectrophotometer po - AD HOC NEWS
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026 - BioSpace
Press Release: Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026 - Moomoo
Form 4 Thermo Fisher Scientific For: 30 June By Investing.com - Investing.com Canada
Thermo Fisher (NYSE: TMO) director awarded new phantom stock units as deferred pay - Stock Titan
Thermo Fisher (TMO) director adds phantom stock units via deferred pay grant - Stock Titan
Thermo Fisher (NYSE: TMO) director awarded new phantom stock units - Stock Titan
Thermo Fisher (NYSE: TMO) director defers fees into phantom stock units - Stock Titan
Thermo Fisher (TMO) director receives phantom stock unit award under deferred plan - Stock Titan
Thermo Fisher Scientific’s PPD Clinical Research Business Collabo - The National Law Review
AustinPx Expands KinetiSol™ Technology Commercial Access through Thermo Fisher Scientific Collaboration - 01net
Thermo Fisher Scientific Expands HLA-DQ Testing Coverage for Transplant Antibody Assessment - Clinical Lab Products
Thermo Fisher Scientific Earnings Preview: What to Expect - Yahoo Finance
Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 Billion - MSN
Genedrive Teams Up with Thermo Fisher Scientific to Develop Laboratory-based Genetic Test - marketscreener.com
genedrive shares climb 8% on Thermo Fisher pharmacogenetic testing deal - Proactive Investors
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.57%
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):